Search clinical trials for: CUTAQUIG

Total 5 results

Octapharma

Completed

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency Disorder

United States
Ottawa Hospital Research Institute
Octapharma

Unknown

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Primary Immunodeficiency Disease | Secondary Immunodeficiency

Canada
Federal Research Institute of Pediatric Hematology...

Recruiting

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Primary Immunodeficiency Diseases (PID)

Russian Federation
University of Alberta
Octapharma

Recruiting

Observational Study of Subcutaneous Immunoglobulin (Cutaquig) in Patients With Primary and Secondary Immunodeficiency.

Primary Immune Deficiency Disorder | Secondary Immune Deficiency

Canada
Merck Sharp & Dohme LLC

Completed

A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)

Type 1 Diabetes Mellitus

3

Subscribe